An ongoing dialogue on HIV/AIDS, infectious diseases,
March 1st, 2011
Like It or Not, PrEP Enters the Clinic
Since the publication of iPrEx, the hypothetical decision about whether to prescribe pre-exposure prophylaxis (PrEP) has become a practical reality.
As a result, we’ve posted a case on the Journal Watch/AIDS Clinical Care site, describing someone who requests intermittent pre-exposure prophylaxis to prevent HIV.
It’s a high-risk, HIV-negative man who’s been treated several times with post-exposure prophylaxis. The case was adapted from someone seen recently in our practice, and it raised many questions about what to do in this newly minted area. As there are obviously no “right” answers, we had a broad range of responses within our group. We’ve asked experts in the field to weigh in as well and will publish those responses shortly.
In the meantime, what have you been doing with requests for PrEP? Have you found the “Guidance” (note that these are not yet “Guidelines”) useful? Any helpful or just interesting anecdotes or opinions you wish to share?
Categories: Antiretroviral Rounds, HIV, Patient Care, Policy
Tags: HIV, pre-exposure prophylaxis, PrEP, TDF/FTC, tenofovir, Truvada
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
One Response to “Like It or Not, PrEP Enters the Clinic”

Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
- The Best Guide to HIV Drug Names — Yours for Free!
- Vaccine Defenders, U=U Holds Up, Zika Is Gone, and Other ID Things to Be Grateful For, 2019 Edition
- A Midyear Letter to First-year ID Fellows — With Sympathy, Gratitude, and Hope!
- When TV Gets ID Wrong — Or At Least Not Quite Right
- The Most Common Question About the New HIV Testing Algorithm, Answered
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Winner of ID Cartoon Caption Contest #3, and Here’s #4 Just in Time for CROI (66)
- Your Next ID Cartoon Caption Contest — Yearning for Your Submission (62)
- HIV and Hepatitis C Are No Longer the Most Serious Infectious Threats to People Who Inject Drugs (60)
-
Subscribe to HIV and ID Observations via Email
NEJM Journal Watch — Recent Infectious Disease Articles
- Longer-Term Results with Doravirine-Based Treatment for HIV
- Two Antibody-Based Ebola Treatments Improve Survival
- Primary Care Clinicians Can Play a Critical Role in Ending the HIV Epidemic
- Observations from ID and Beyond: On World AIDS Day 2019 — Wouldn't It Be Nice …?
- Real-World Experience Transplanting Hepatitis C Seropositive Livers into Seronegative Recipients
-
Physician's First WatchToday's breaking medical news
-
Tag Cloud
- 3tc Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff CROI cure darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza lamivudine Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir vaccines zoster
Great discussion points on PrEP. GHDonline is partnering with MGH’s HOPE Conference Serires to host a “virtual discussion” on PrEP in practice next week. Would love for you to jump into the conversation and summarize it here on your blog.
http://www.ghdonline.org/hivprevention/discussion/march-7-11-ghdonline-to-host-virtual-panel-discuss/
Panelists from Uganda, South Africa and the United States will add discussions to the online community, highlighting various barriers and opportunities to implementing PrEP in clinical settings; how to encourage long-term adherence; and what additional research questions need to be answered.
All GHDonline members can participate in this virtual discussion. Sign up here if you haven’t already joined and keep your email settings to “per post” to track the discussion live in your inbox.
Panelists:
Douglas Krakower, MD is a fellow in Infectious Diseases at Beth Israel Deaconess Medical Center/Harvard Medical School
Andrew Mujugira, MBChB, MSc is the East Africa regional medical director for the Partners PrEP study.
Vivek Naranbhai, PhD, was involved in CAPRISA microbicide gel study.